Recombinant antibodies are among the most important classes of modern biotherapeutics. Their ability to recognize and bind targets with high specificity has transformed treatment strategies across oncology, immunology, and infectious disease. As biological understanding has advanced, demand has increased for antibodies that can do more than bind a single target in a standard configuration, particularly across biopharmaceutical research, therapeutic development, and diagnostic innovation.
Advances in protein engineering and expression technologies have enabled the development of diverse antibody formats that can be tailored to specific biological functions, pharmacokinetic profiles, and therapeutic needs. These formats differ in molecular architecture, functional capabilities, and manufacturing complexity, making format selection a critical early decision in any antibody discovery program.
Most therapeutic antibodies are based on the Immunoglobulin G (IgG) structure. IgG molecules typically consist of two identical heavy chains and two identical light chains linked by disulfide bonds, forming a Y-shaped structure.
The antigen-binding regions, located in the Fab domain, provide high specificity for target molecules. Meanwhile, the Fc region mediates immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) and interacts with the neonatal Fc receptor to prolong serum half-life. This combination of specificity, stability, and well-established manufacturing pathways has made IgG the dominant format in therapeutic development. IgG is also the most extensively characterized antibody format in regulatory submissions, with established precedent across all major agencies including the FDA, EMA, and PMDA. However, as therapeutic goals become more complex, alternative formats have emerged to address limitations in size, flexibility, and functionality.
To meet diverse biological challenges, researchers have developed a range of engineered antibody formats that build on or deviate from IgG structure. The format chosen affects not only biological activity but also expression system selection, manufacturing scalability, and regulatory pathway. Understanding the trade-offs between formats is essential for any antibody discovery or development program.
| Antibody-format | Structure | Advantages | Applications |
| Monoclonal IgG | Two identical heavy chains and two identical light chains linked by disulfide bonds, forming a Y-shaped structure |
|
Oncology, autoimmune, inflammatory, and infectious disease; |
| Antibody Fragments (Fab) | One antigen-binding arm composed of VH, CH1, VL, and CL domains |
|
Receptor blocking, toxin neutralization, diagnostic, and imaging applications |
| scFv | Variable heavy (VH) and light (VL) domains connected by a flexible peptide linker |
|
Targeted CAR-T cell therapies, drug delivery, and molecular imaging agents |
| Nanobodies | Camelid heavy-chain-only antibodies consisting of a single variable domain (VHH) |
|
Inflammatory disease, oncology, respiratory disorder, and central nervous system targeting due to tissue penetration capabilities |
| Bi-specific and Multi-specific Antibodies | Capable of binding two or more different antigens or epitopes simultaneously, with a range of formats |
|
Oncology, autoimmune and infectious disease |
Format selection depends on several intersecting factors. Full-length IgG remains the default choice when long half-life, Fc effector function, and a clear regulatory path are priorities. Antibody fragments and scFv constructs are preferred when tissue penetration, rapid clearance, or bacterial expression is required. Nanobodies are increasingly favored for targets with sterically hindered or cryptic epitopes, and for applications requiring extreme stability such as inhaled formulations or high-temperature environments. Bispecific formats are best suited to programs where simultaneous engagement of two targets or immune cell redirection is central to the mechanism of action.
Learn more about recombinant antibody design and production or contact our scientific team to discuss your program requirements.
Nanobodies are derived from camelid heavy-chain-only antibodies and consist of a single variable domain (VHH), making them the smallest functional antibody fragments available. scFv constructs link the heavy and light variable domains of a conventional antibody with a peptide linker. Nanobodies are generally more stable, more soluble, and better able to access recessed epitopes, while scFv formats offer greater design flexibility and are well suited for fusion proteins and CAR-T constructs.
Full-length IgG antibodies are most commonly produced in mammalian expression systems such as CHO or HEK293 cells, which support the post-translational modifications required for proper folding and Fc function. Smaller formats such as scFv and nanobodies can be expressed efficiently in bacterial systems like E. coli or in yeast, which lowers production costs and speeds timelines for early-stage research.
Bispecific antibodies are engineered to bind two different antigens or two different epitopes on the same antigen simultaneously. They are most widely used in oncology to redirect T cells toward tumor cells, as in T cell-engaging bispecifics, and to block two signaling pathways at once. Multiple bispecific formats exist, ranging from full IgG-like structures to smaller tandem scFv and diabody configurations.
Fc engineering involves modifying the Fc region of an IgG to enhance or silence effector functions, extend or shorten serum half-life, or reduce immunogenicity. Common modifications include amino acid substitutions that increase ADCC activity, mutations that extend half-life through improved FcRn binding, and aglycosylated variants that reduce Fc receptor engagement for applications where immune activation is undesirable.
About the authors: Prassanna Rao and Fränze Vorreiter are Synthesis Experts at GENEWIZ. They and their team translate complex biological challenges into precise, actionable solutions for researchers worldwide. Their expertise spans designing complex cloning strategies for de novo synthesis, synthetic libraries, recombinant antibody production, and viral production services.